CINECA IRIS Institutional Research Information System

CUSATO, Jessica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.308
EU - Europa 5.713
AS - Asia 2.042
AF - Africa 116
SA - Sud America 68
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 16
Totale 18.294
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.213
IT - Italia 1.237
DK - Danimarca 1.179
CN - Cina 1.101
IE - Irlanda 654
SE - Svezia 550
FR - Francia 413
DE - Germania 356
FI - Finlandia 244
UA - Ucraina 240
SG - Singapore 239
AT - Austria 183
GB - Regno Unito 169
IN - India 144
VN - Vietnam 129
PL - Polonia 117
KR - Corea 111
JP - Giappone 95
NL - Olanda 95
CA - Canada 70
ZA - Sudafrica 56
BE - Belgio 52
ES - Italia 50
HK - Hong Kong 46
BR - Brasile 40
TH - Thailandia 36
CZ - Repubblica Ceca 32
TW - Taiwan 30
AU - Australia 29
GR - Grecia 29
ID - Indonesia 25
CH - Svizzera 22
RU - Federazione Russa 22
TR - Turchia 21
MX - Messico 19
RO - Romania 18
PK - Pakistan 16
EU - Europa 13
UZ - Uzbekistan 13
NG - Nigeria 11
PT - Portogallo 10
RS - Serbia 9
SN - Senegal 9
CL - Cile 8
EG - Egitto 7
IR - Iran 7
UG - Uganda 7
AR - Argentina 6
CO - Colombia 6
HR - Croazia 6
KE - Kenya 6
EC - Ecuador 5
IQ - Iraq 5
NO - Norvegia 5
BG - Bulgaria 3
DZ - Algeria 3
KZ - Kazakistan 3
LV - Lettonia 3
MA - Marocco 3
MK - Macedonia 3
MU - Mauritius 3
PH - Filippine 3
PS - Palestinian Territory 3
AE - Emirati Arabi Uniti 2
AP - ???statistics.table.value.countryCode.AP??? 2
CR - Costa Rica 2
ET - Etiopia 2
GA - Gabon 2
HU - Ungheria 2
LI - Liechtenstein 2
ME - Montenegro 2
MY - Malesia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
A1 - Anonimo 1
AF - Afghanistan, Repubblica islamica di 1
BD - Bangladesh 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CU - Cuba 1
CY - Cipro 1
GE - Georgia 1
GM - Gambi 1
HN - Honduras 1
IL - Israele 1
JO - Giordania 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
MZ - Mozambico 1
NA - Namibia 1
PA - Panama 1
PE - Perù 1
PR - Porto Rico 1
SY - Repubblica araba siriana 1
Totale 18.292
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.476
Chandler 1.340
Dublin 648
Beijing 631
Fairfield 561
Houston 443
Torino 427
Ashburn 340
Woodbridge 313
Wilmington 301
Dearborn 293
Nyköping 289
Villeurbanne 285
Seattle 211
Medford 200
Princeton 199
Vienna 176
Cambridge 170
Redwood City 168
Singapore 157
Jacksonville 147
Turin 114
Warsaw 101
Pisa 87
New York 84
Fremont 82
Dong Ket 63
Milan 62
Nanjing 52
Boardman 51
Boston 50
Guangzhou 44
Shanghai 40
Brussels 36
San Diego 36
Toronto 34
Helsinki 32
Los Angeles 32
Norwalk 32
Washington 32
Brno 28
Hangzhou 28
Hefei 27
Rome 25
Verona 24
Hebei 22
Taipei 22
Hong Kong 21
Munich 21
Chengdu 19
London 19
Falls Church 17
Jinan 17
Chicago 16
Mountain View 16
Seoul 16
Cape Town 15
Phoenix 15
Dallas 14
Florence 14
Kunming 14
Nanchang 14
Shenzhen 14
Tokyo 14
Alberton 12
Amsterdam 12
Lappeenranta 12
Mumbai 12
Paris 12
Pune 12
Rotterdam 12
Jakarta 11
Kharkiv 11
Xian 11
Bengaluru 10
Montreal 10
Nürnberg 10
Piemonte 10
Silver Spring 10
Chongqing 9
Esslingen am Neckar 9
Hyderabad 9
Minneapolis 9
Ottawa 9
Philadelphia 9
Upper Marlboro 9
Belgrade 8
Chennai 8
Chiang Mai 8
Copenhagen 8
Des Moines 8
Edinburgh 8
Genoa 8
San Mateo 8
Bangkok 7
Bologna 7
Buffalo 7
Central District 7
Gurgaon 7
Islamabad 7
Totale 11.627
Salva come PNG Salva come JPEG
Nome #
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. 408
Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children 384
Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. 331
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 309
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 300
The E genotype of hepatitis B: Clinical and virological characteristics, and response to interferon 297
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 275
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 269
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 269
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 248
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 238
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 237
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 234
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. 230
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 229
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 220
Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. 214
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. 211
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 201
Descrittiva della farmacocinetica (PK) e della farmacogenetica (PG) dell'Efavirenz in una coorte di popolazione italiana 197
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 190
Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B 186
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. 183
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment 181
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 178
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 174
ITPA gene variants as markers of ribavirin-induced anemia and white blood cells reduction in Egyptian HCV patients 172
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 169
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 166
PHARMACOGENETIC DETERMINANTS OF PLASMATIC AND INTRACELLULAR TYROSINE KINASE INHIBITORS 165
Role of pharmacogenetics on deferasirox AUC and efficacy 163
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 162
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D 160
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia 160
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 159
The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study 159
Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. 153
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 153
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 153
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 153
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 152
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 151
Genetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 151
Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia 149
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 147
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 146
Discordant results for IL28B genotyping (rs12979860 vs. rs8099917) and the prediction of rapid viral response in chronic hepatitis C 141
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 140
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 139
A simple high performance liquid chromatography-mass spectrometry method for Therapeutic Drug Monitoring of isavuconazole and four other antifungal drugs in human plasma samples 136
Pharmacogenetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 135
Influenza della somministrazione del metadone sulle concentrazioni plasmatiche di daclatasvir in una coorte di pazienti con epatite cronica da HCV e tossicodipendenza attiva. 135
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 134
Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection 133
25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2 131
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 131
Pharmacogenetics of ribavirin-induced anemia in HCV patients 130
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. 130
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 128
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs 126
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 125
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon 123
Ruolo della riduzione precoce di HBsAg per individuare i pazienti con infezione precoce da HBV, HBeAg-negativi e genotipo E ad alta probabilità di risposta sostenuta con 48 settimane di trattamento con PEG-INF ALFA-2A 120
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children 117
VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. 115
Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study 110
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 106
Cannabinoids concentration variability in cannabis olive oil galenic preparations 106
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 101
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma 98
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir 98
Estimating ribavirin plasma exposure: Genetics or therapeutic drug monitoring? 94
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 93
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children 93
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes 93
A description of Cannabinoid levels in Cannabis oil by high-performance liquid chromatography-mass spectrometry in a reference laboratory of North-Italy 93
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients 90
Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients 88
Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs 88
The "scar" of a pandemic: cumulative incidence of COVID-19 during the first trimester of pregnancy 86
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness. 85
Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon 85
A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples 85
Pharmacokinetics of simeprevir and risk of skin reactions in patients with co-infection HIV/HCV with or without a protease inhibitor containing HAART 84
Deferasirox AUC efficacy cutoff and role of pharmacogenetics 84
Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients 84
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 83
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV 83
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy 83
Efavirenz pharmacogenetics in a cohort of Italian patients 81
Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots 81
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 78
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness 76
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 75
Real life Study on the Pharmacokinetic of Remdesivir in ICU patients admitted for Severe COVID-19 Pneumonia 75
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 74
Clinical relevance of deferasirox trough levels in β-thalassemia patients 74
Genetic determinants of mitotane pharmacokinetics in adrenocortical cancer patients 73
Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations 73
Totale 15.109
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.374
article - articoli 0
book - libri 0
conference - conferenze 10.215
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.589
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.312 0 87 91 266 362 662 285 185 222 371 352 429
2020/20212.213 323 113 76 128 144 165 108 78 188 165 287 438
2021/20224.029 326 309 340 378 271 366 363 299 209 153 545 470
2022/20233.803 353 335 137 329 342 890 223 323 405 97 255 114
2023/20241.581 207 262 108 70 98 209 60 81 35 77 138 236
2024/202577 75 2 0 0 0 0 0 0 0 0 0 0
Totale 19.283